Amundi Grows Holdings in Enovis Corporation $ENOV

Key Points

• Amundi increased its Enovis stake by 397.7% in the second quarter, holding 369,189 shares worth approximately $7.6 million. Institutional investors collectively own 98.45% of the company.
• Enovis insiders have also been buying shares: the CEO and another insider purchased a combined 18,175 shares in early September, while insiders bought 24,293 shares worth about $470,519 over the past 90 days.
• Enovis recently beat quarterly earnings and revenue estimates, but its stock opened at $19.54—near its one-year low of $18.08. Analysts maintain a “Moderate Buy” consensus with an average price target of $40.38.

Amundi boosted its holdings in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 397.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 369,189 shares of the company's stock after acquiring an additional 295,005 shares during the period. Amundi owned 0.64% of Enovis worth $7,642,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of ENOV. Dimensional Fund Advisors LP increased its stake in shares of Enovis by 1.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company's stock valued at $90,156,000 after purchasing an additional 51,201 shares in the last quarter. Rubric Capital Management LP bought a new stake in Enovis in the third quarter worth $83,435,000. Paradigm Capital Management Inc. NY grew its stake in shares of Enovis by 70.2% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock worth $40,420,000 after acquiring an additional 732,917 shares during the last quarter. River Road Asset Management LLC grew its stake in shares of Enovis by 3.2% in the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company's stock worth $39,621,000 after acquiring an additional 46,289 shares during the last quarter. Finally, Private Management Group Inc. increased its holdings in shares of Enovis by 38.8% during the second quarter. Private Management Group Inc. now owns 1,365,082 shares of the company's stock valued at $28,257,000 after acquiring an additional 381,705 shares in the last quarter. Institutional investors own 98.45% of the company's stock.

Insider Activity

In related news, CEO Damien Mcdonald acquired 13,035 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The stock was purchased at an average cost of $19.15 per share, with a total value of $249,620.25. Following the transaction, the chief executive officer directly owned 247,077 shares of the company's stock, valued at $4,731,524.55. This trade represents a 5.57% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Oliver Engert bought 5,140 shares of the company's stock in a transaction on Thursday, September 3rd. The shares were bought at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the transaction, the insider owned 61,238 shares in the company, valued at $1,191,691.48. The trade was a 9.16% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 24,293 shares of company stock worth $470,519. Corporate insiders own 2.90% of the company's stock.

Enovis Stock Performance

Shares of Enovis stock opened at $19.54 on Friday. The company has a market capitalization of $1.13 billion, a PE ratio of -1.01 and a beta of 1.31. The company has a 50-day simple moving average of $25.25 and a two-hundred day simple moving average of $24.10. Enovis Corporation has a one year low of $18.08 and a one year high of $34.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm had revenue of $582.78 million during the quarter, compared to analysts' expectations of $581.84 million. During the same quarter last year, the firm earned $0.79 EPS. The business's quarterly revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts expect that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ENOV has been the subject of several recent analyst reports. Zacks Research raised shares of Enovis from a "strong sell" rating to a "hold" rating in a report on Wednesday, July 29th. Weiss Ratings upgraded shares of Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 21st. Citizens Jmp reduced their price target on shares of Enovis from $55.00 to $47.00 and set a "market outperform" rating for the company in a research report on Wednesday, September 2nd. Citigroup restated a "market outperform" rating on shares of Enovis in a report on Wednesday, September 2nd. Finally, Canaccord Genuity Group lowered their price objective on Enovis from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Monday, August 17th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.38.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company's product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.